SCHEMBL4015010

SCHEMBL4015010

Clc1ccc(Nc2cccc(-n3ncc4ccccc43)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 2/20 0.46
CDK1 P06493 2/20 0.46
CCNB1 P14635 2/20 0.46
CDK9 P50750 2/20 0.46
CDK7 P50613 1/20 0.46
CCNH P51946 1/20 0.46
EGFR P00533 1/20 0.42
ERBB3 P21860 1/20 0.42
SCN9A Q15858 1/20 0.42
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
MAPT P10636 6/20 0.39
KDM4E B2RXH2 4/20 0.39
RAB9A P51151 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALPG P10696 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NPC1 O15118 2/20 0.38
LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2891366 0.86 CDK2 (0.44) CCNT1CDK1CCNB1CDK9CDK7
SCHEMBL4014146 0.78 EGFR (0.41) EGFRERBB3SCN9ACNR1CNR2
SCHEMBL12075159 0.76 MKNK1 (0.46) CCNT1CDK1CCNB1CDK9CDK7
SCHEMBL4014605 0.75 NPC1 (0.50) MAPTKDM4ERAB9AMEN1KMT2A
SCHEMBL3571139 0.72 MAPT (0.54) EGFRERBB3CNR1CNR2MAPT
SCHEMBL16740282 0.72 BMI1 (0.50) MAPTKDM4ERAB9ANPC1LMNA
SCHEMBL29496843 0.72 NPC1 (0.61) KDM4ERAB9AMEN1KMT2ANPC1
SCHEMBL3577903 0.71 NOTUM (0.49) EGFRERBB3SCN9ACNR1CNR2
SCHEMBL3579788 0.71 SCN9A (0.42) EGFRERBB3SCN9ACNR1CNR2
SCHEMBL23840290 0.69 PDE10A (0.45) CCNT1CDK1CCNB1CDK9CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325989-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2009-12-31 US claimed
US-8222262-B2 Indazolyl derivatives useful as potassium channel modulating agents NEUROSEARCH A/S (DK) 2012-07-17 US disclosed
US-8222262-B2 Indazolyl derivatives useful as potassium channel modulating agents NEUROSEARCH A/S (DK) 2012-07-17 US disclosed
US-8222262-B2 Indazolyl derivatives useful as potassium channel modulating agents NEUROSEARCH A/S (DK) 2012-07-17 US disclosed
US-20090325989-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2009-12-31 US disclosed
US-20090325989-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2009-12-31 US disclosed
US-20090325989-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2009-12-31 US disclosed
EP-2074113-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NeuroSearch A/S (DK) 2009-07-01 EP disclosed
WO-2008040753-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2008-04-10 WO disclosed
WO-2008040753-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325989-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS KCND2, KCNN3, KCNJ2 CCNT1 4212/4885CDK1 1310/4885CCNB1 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.